ERBB2 and gastroesophageal junction adenocarcinoma: Furthermore, in HER2-negative advanced gastric or GEJ adenocarcinoma patients, Lactobacillus was enriched in the gut microbiome of responders to anti-PD-1/PD-L1 therapy and was associated with better PFS [40].